Hisamitsu Pharmaceutical | Sustainability Performance
Produces and markets pharmaceutical products, with a focus on topical medications and treatments.
1847
Japan
1,001 - 5,000 employees
Pharmaceuticals
$1B - 10B in revenue
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#10667
Overallⓘ#502
in Japanⓘ#255
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Financial Data
Business performanceCapital & innovationAnalyst projections
Controversy level
- Hisamitsu Pharmaceutical Co Inc, Japanese transdermal patches (Salonpas major), has faced multiple US FDA Form 483 observations at multiple Hisamitsu production facilities including the contested 2024 enforcement actions on US Salonpas product quality, plus periodic class actions over alleged inadequate disclosure of US OTC analgesic market normalization affecting Japanese institutional shareholders.
